Dysmenorrhea Medications Market Size, Share, and Industry Analysis, By Drug Class (NSAIDs, COX-2 Inhibitor, Hormonal Therapy, and Others), By Indication (Primary Dysmenorrhea and Secondary Dysmenorrhea), By Type (OTC and Prescription), By Distribution Channel (Hospital Pharmacy, Drug Stores & Retail Pharmacies, and Online Pharmacy), and Regional Forecast, 2026-2034

The global dysmenorrhea medications market is growing due to the rising women population and heightened awareness in regards with reproductive health. Dysmenorrhea can be defined as the extreme pain experienced in the lower abdomen during the menstrual cycle. It is one of the most commonly occurring gynecologic problems faced by women across the globe. The pain involves severe intensity and frequent menstrual cramps. It may or may not be a cause of any underlying disease. Long exposure or delay in treatment alternatives can adversely impact mental and physical health. Various lifestyle factors contributing to the condition include smoking, higher or lower body mass index, longer and heavier flow, among others. The medications available for the treatment include NSAIDs, COX-2 inhibitors, and hormonal therapies, among others. They reduce the production to restrict the uterus contraction. These medications help with mitigating symptoms and ease pain. 

Dysmenorrhea Medications Driver

Increased Awareness about Reproductive Health to Drive Market Growth 

Increased awareness of menstrual and reproductive health among women has led to increasing diagnostic among females. Rather than dismissal of pain, this heightened awareness has enabled women to recognize symptoms such as dysmenorrhea to identify underlying conditions. As awareness rises, so does demand for professional care and pharmaceutical solutions, creating favorable conditions for market expansion in menstrual health products and services.

• For instance, in June 2025, the Himalayan Journal of Applied Medical Sciences and Research published an article titled Public Awareness and Knowledge of Menstrual Disorders and Their Management: A Cross-Sectional Study in Kangra. The article reported a cross-sectional study conducted in Kangra district to assess public awareness and knowledge of menstrual disorders. Among 400 adults who participated in the study, 81.5 % correctly identified dysmenorrhea.

Prevalence (%) of Menstrual Pain in Japanese Women Sofy App Users (%)

In May 2025, Scientific Reports published an article titled ‘Prevalence of menstrual pain and symptoms and their association with age and BMI among Japanese female app users’. The article reported that among 32,556 valid responses, the overall prevalence of menstrual pain was 66.83%, with 28.3% reporting mild pain, 25.1% moderate pain, and 13.3% severe pain.

Dysmenorrhea Medications Restraint

Normalization of Pain and Non-Pharmacological Alternatives to Restrict Market Growth Potential

Normalization of pain and tendency to self-manage it with non-pharmacological alternatives such as heat application, coupled with reluctance for usage of medications, is to restrict growth. The normalization of pain has led to a misconception of dysmenorrhea as a tolerable and natural condition. These factors discourage the medical consultation and push toward self-management strategies such as heat application. Such behavior limits the pharmaceutical medication treatments, despite their availability and efficacy. Such factors limit the growth potential of the market.

• For instance, in November 2021, BMC Women's Health published a report titled ‘Prevalence, risk factors, and management practices of primary dysmenorrhea among young females’. The report stated that in a meta-analysis, comprising 12,526 females, 51.8% of females adopted different non-pharmacological measures to cope with their menstrual pain.

Dysmenorrhea Medications Opportunity

Ongoing Clinical Trials to Offer Novel Therapies for Dysmenorrhea to Offer Lucrative Growth Avenues

For Market Growth

At present, the dysmenorrhea medication market is highly reliant on NSAIDs and hormonal therapies. Many women are unresponsive to NSAIDs. Due to these factors, research and development are being carried out for the development of novel therapies. Numerous ongoing trials to offer novel treatments for dysmenorrhea offer lucrative growth opportunities.

• For instance, in September 2024, Organon K.K. reported positive results in a Phase III clinical trial evaluating the efficacy and safety of OG-8276A, being developed as a treatment for dysmenorrhea. 

Key Insights

The report covers the following key insights:

• Epidemiology of Dysmenorrhea
• Overview: Current Treatment & Therapies for Dysmenorrhea
• Pipeline Analysis, By Key Players
• Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)

Segmentation

Analysis by Drug Class

Based on drug class, the global dysmenorrhea medication market is classified into NSAIDs, COX-2 inhibitors and hormonal therapy, and others. 

Among these, NSAIDs are expected to account for a significant segmental share in the market. The high share of the segment is attributed to U.S. FDA approvals for the treatment of dysmenorrhea and its easy administration. These medications use prostaglandins to relieve uterus cramps and relieve pain efficiently—also, regulatory approval to boost the growth of the segment.

• For instance, in July 2025, Zydus Lifesciences Limited received approval from the U.S. FDA for Celecoxib Capsules, a nonsteroidal anti-inflammatory drug to treat pain or inflammation caused by many conditions, such as menstrual pain, ankylosing spondylitis, and arthritis. 

Analysis by Indication

By indication, the market is divided into primary dysmenorrhea and secondary dysmenorrhea.

The secondary dysmenorrhea is expected to hold a dominant share in the market. While primary dysmenorrhea does not highlight any underlying diseases, secondary dysmenorrhea can indicate various underlying female reproductive diseases such as endometriosis, fibroids, and pelvic inflammatory disease. Higher pain associated with the onset of periods gets worse over the course. Such factors led to a higher segmental share of secondary dysmenorrhea.

• For instance, as per the study published by BMC Women’s Health, which recruited 1,199 Saudi women aged 18–45 in Riyadh using systematic random sampling. The findings showed that 92.3% had primary dysmenorrhea, while 7.7% had secondary dysmenorrhea. However, secondary dysmenorrhea is more intense, longer-lasting, and can persist beyond menstruation. Thus, such conditions increase the adoption of medication and propel the segment’s growth.

Analysis by Type

By type, the market is divided into OTC and prescription.

The OTC segment is expected to hold a leading market position. The tendency of self-management for pain relief for menstrual pain and the easy availability of OTC drugs are driving the market. OTC drugs for pain relief, such as NSAIDs, are highly used.

• For example, in March 2023, Perrigo Company plc received approval from the U.S. FDA for its Abbreviated New Drug Application for Acetaminophen and Ibuprofen Tablets, 250 mg/125 mg, the store brand over-the-counter equivalent of Advil Dual Action Tablets 250 mg/125 mg. Such developments are expected to drive the growth of the segment.

 Analysis by Distribution Channel

By distribution channel, the market is divided into hospital pharmacy, drug stores & retail pharmacies, and online pharmacy.

The drug stores and retail pharmacies are expected to grow with a significant CAGR over the upcoming years. Nonsteroidal anti-inflammatory drugs such as ibuprofen, diclofenac, naproxen, mefenamic acid, and ketoprofen, commonly used for treating primary dysmenorrhea, are easily available in all retail stores. These are non-prescription OTC drugs that can penetrate remote areas due to the optimum distribution channel of drug stores and retail. Also, new retail pharmacy openings worldwide contribute to the robust distribution of retail pharmacies.

• For instance, in July 2025, CVS Health unveiled a new Philadelphia CVS Pharmacy. The new store offers expanded pharmacy and private consultation and vaccination area, an improved in-store delivery pickup area, among other benefits.

Regional Analysis

By region, the market is divided into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Request for Customization   to gain extensive market insights.

North America is expected to dominate the global dysmenorrhea medication share. The regional growth of the market presence of key companies, along with increasing awareness and robust healthcare infrastructure. Due to these factors, the region attracts attention from various key players.

• For instance, in August 2021, Dr. Reddy’s announced the re-launch of OTC Naproxen Sodium Tablets USP, 220 mg, store-brand equivalent of Aleve in the U.S. Market. The drug temporarily relieved minor aches and pains caused by minor pain of arthritis, muscular aches, backache, menstrual cramps, headache, toothache, and the common cold.

Europe is expected to account for a considerable regional share over the forecast period. The high share allocated to the region is due to novel product launches, increasing research and development, and high product adoption in the region.

• For instance, in September 2024, Kissei Pharmaceutical Co., Ltd. launched YSELTY for uterine fibroid treatment in Germany. One of the symptoms of the disease is dysmenorrhea. Such developments support the growth of the market in the region.

Asia Pacific is expected to grow with a substantial CAGR during the forecast period. The significant growth rate in the region is attributed to rising awareness of menstrual health through integration of schools and educational institutes, along with increased healthcare spending and government support, such factors expected to drive the growth of the region in the forthcoming years. 

Key Players Covered

The global dysmenorrhea medications market is fragmented with the presence of several established and emerging companies. The report includes the profiles of the following key players:

• Pfizer Inc. (U.S.)
• GSK plc (U.K)
• Bayer AG (Germany)
• Novartis AG(Switzerland)
• Sanofi (France)
• Merck & Co., Inc. (U.S.)
• Viatris (U.S.)
• Zydus Lifesciences (India)
• Teva Pharmaceutical Industries Ltd. (Israel)

Key Industry Developments

• In September 2024, ASKA Pharmaceutical Co., Ltd., in collaboration with TechDoctor, Inc. and launched the joint research on dysmenorrhea in cooperation with the healthcare app 4MOON. 
• In August 2022, Myovant Sciences collaborated with Pfizer Inc. They received approval from the U.S. FDA for MYFEMBREE as therapy for the management of moderate to severe pain associated with endometriosis in pre-menopausal women, with a treatment duration of up to 24 months.